Sanders Morris Harris’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Sanders Morris Harris’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-460	Closed	-$115K	–	313
2022 Q1	$115K	Buy	+460	New	+$72.7K	0.02%	285
2020 Q1	–	Sell	-1,583	Closed	-$691K	–	286
2019 Q4	$691K	Buy	1,583 +533	+51%	+$189K	0.16%	138
2019 Q3	$302K	Hold	1,050	–	–	0.07%	206
2019 Q2	$344K	Buy	+1,050	New	+$364K	0.09%	194

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sanders Morris Harris's EIGR Position: Q2 2022 in Review

Sanders Morris Harris sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2022, closing a stake of 460 shares — an estimated $115K sold.

Sanders Morris Harris first reported a position in EIGR in Q2 2019 and held it in 4 quarters. The position peaked at $691K in Q4 2019. 91 funds tracked by Wall St. Rank hold EIGR as of Q2 2022.

Sanders Morris Harris reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
Sanders Morris Harris sold 460 Eiger BioPharmaceuticals, Inc. shares in Q2 2022, an estimated $115K.
Sanders Morris Harris first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2019 and held it in 4 quarters.
Sanders Morris Harris's Eiger BioPharmaceuticals, Inc. position peaked at $691K in Q4 2019.
91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2022.

Based on Sanders Morris Harris's 13F filing for Q2 2022, filed 11 Jul 2022.